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Abstract: Hypoxia-Inducible Factors (HIFs) play essential roles in the physiological response to low 
oxygen in all multicellular organisms, while their deregulation is associated with human diseases. 
HIF levels and activity are primarily controlled by the availability of the oxygen-sensitive HIFα 
subunits, which is mediated by rapid alterations to the rates of HIFα protein production and 
degradation. While the pathways that control HIFα degradation are understood in great detail, 
much less is known about the targeted control of HIFα protein synthesis and what role this has in 
controlling HIF activity during the hypoxic response. This review will focus on the signalling 
pathways and RNA binding proteins that modulate HIFα mRNA half-life and/or translation rate, 
and their contribution to hypoxia-associated diseases.  
Keywords: Hypoxia; HIF; Translation; Protein Synthesis; mRNA; RNA binding Proteins; RBP; 
Micro RNAs; MiR 
 
1. Introduction 
Respiration in human cells strictly depends on balancing oxygen levels to support aerobic 
respiration, without producing excessive reactive oxygen species that can result in damage to 
organelles [1,2]. An increase (hyperoxia) or decrease (hypoxia) in cellular oxygen levels, leads to the 
activation of cellular signalling pathways that allow cells and organisms to maintain oxygen 
homeostasis [1,2]. Oxygen levels are therefore tightly regulated in cells and tissues. However, 
hypoxia and the activation of hypoxia-induced cellular signalling pathways are a common 
denominator in the pathophysiology of human diseases [1,3]. As such, insight into how human cells 
detect and respond to low oxygen is crucial to understanding the role of the hypoxic response in 
disease.  
2. Hypoxia-Inducible Factors 
Central to the hypoxic response are the Hypoxia-Inducible Factors (HIFs). HIFs are transcription 
factors essential for the adaptive response to low oxygen and the primary mediator of gene 
expression changes in hypoxic cells [1,2]. HIFs are activated in cells where oxygen levels fail to meet 
demand, at a point that is context dependent due to variations in oxygen requirements between cells 
and tissues within the human body (~100 mmHg in arterial blood to ~29 mmHg in muscle) [4]. This 
may be caused by chronic hypoxia due to oxygen deprivation, or cyclic hypoxia, wherein oxygen 
levels fluctuate significantly within the tissue microenvironment [5,6]. HIF was first recognised as a 
DNA-binding α/β-heterodimer that binds to an enhancer region of the human erythropoietin gene to 
promote its expression and stimulate red blood cell production [7]. HIF transcription factors are 
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found in all human cell types and are recognised as key modulators of the transcriptional response 
to hypoxia [1,2]. HIF transcription factors play essential roles for the acute response to low oxygen in 
normal cells and tissues. However, deregulated HIF activity is frequently observed in malignant cells 
where it can induce changes in energy metabolism and protect cells from hypoxia-induced cell death 
[1,8–10]. To date, more than 100 direct HIF target genes have been identified, many of which have 
been shown to be involved in the control of the metabolic switch for optimal cellular adaptation to 
hypoxia, angiogenesis, energy metabolism, cell differentiation and apoptosis, all of which have 
important roles in normal cell function, but can contribute to disease pathogenesis [3,11,12].  
The HIFα and HIFβ subunits are DNA-binding proteins that form transcriptionally active 
heterodimeric complexes to activate hypoxia responsive genes [3,9]. The human genome contains 
three HIFα subunits (HIF1α, HIF2α/EPAS, and HIF3α) and two HIFβ subunits (ARNT/HIF1β and 
ARNT2) [3,9]. HIF subunits share highly similar domain regions, characterised by the presence of 
bHLH (basic helix–loop–helix)–PAS (Per/ARNT/Sim) domains that mediate heterodimer formation 
and DNA binding [13]. In addition to these shared domains, HIFα subunits contain oxygen-
dependent degradation (ODD) domains and transactivation domains (TAD) to promote the 
expression of target genes [14]. The two principle HIF complexes are comprised of HIF1β, and one of 
either HIF1α or HIF2α, which make up the transcription factors referred to as HIF1 and HIF2, 
respectively [1,9]. Despite their structural similarities and identical DNA recognition motifs, HIF1 
and HIF2 are activated with different kinetics and bind to a distinct repertoire of cell-specific sites 
across the genome [15,16]. HIF3α cannot induce the expression of hypoxia-inducible target genes to 
the same extent as HIF1α and HIF2α as it lacks the C-terminal TAD [17]. HIF3α can, therefore, act as 
a suppressor of HIF-dependent gene expression by competing with HIF1α or HIF2α to bind HIF1β, 
or other binding partners for HREs in the promotors of target genes [1,17]. 
Targeted disruptions to either HIF1α or HIF2α in mice results in early embryonic lethality. 
However, the phenotypes are markedly different, with HIF1α-/- mice dying by E11 with severe 
angiogenensis defects and HIF2α-/- mice suffering from bradycardia, abnormal lung formation and 
blood vessel defects that kills the majority of embryos by E14 [18–20]. In comparison, HIF3α-/- mice 
appear outwardly normal, and have relatively mild phenotype associated with heart development 
and lung remodelling [21]. The available data indicate that individual HIFα subunits play distinct 
and separate roles in physiology and disease [16]. This review will focus on the control of protein 
translation of the individual HIFα subunits, mainly concentrating on regulation of the HIF1α and 
HIF2α subunits, as a means of regulating HIF activity in response to hypoxic stress, and importantly, 
how HIF translation may be directed therapeutically to target-specific HIF complexes. 
3. Control of HIF Activity by Ubiquitin-Mediated Proteolysis 
In well-oxygenated cells, both HIF1α and HIF2α are continuously synthesised prior to being 
hydroxylated on conserved proline residues within their ODD domains by a family of prolyl-
hydroxylase enzymes (PHD-1-4) [1,2,22]. The hydroxylated HIFα subunits are recognised by the von 
Hippel–Lindau (VHL) E3 ubiquitin ligase, which promotes the ubiquitination and subsequent 
degradation of HIF1α and HIF2α by the 26S proteasome1 [2]. When oxygen levels are reduced, the 
PHD enzymes are inhibited, resulting in HIF1α and HIF2α stabilisation and nuclear translocation 
[1,2]. When in the nucleus HIF1α and HIF2α can form heterodimers with HIFβ and activate the 
expression of hypoxia-responsive genes. 
Much has been done to unravel the series of post-translational modifications required to control 
HIFα protein degradation (reviewed extensively [1,2]). However, considerably less is understood 
about the mechanisms that control HIFα subunit protein synthesis. Despite the identical modulation 
of HIF1α and HIF2α proteins by the PHD/VHL-dependent pathway, the available evidence suggests 
that HIF1 and HIF2 are disparately regulated within the cell [16]. Thus, alternative mechanisms must 
exist to independently control HIFα subunit levels in the cell. As regulation of protein abundance is 
ultimately controlled by the interplay between mRNA transcription, protein translation and protein 
degradation, intervention at each stage can define absolute protein levels. Control of HIF subunit 
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mRNA translation is an important mechanism to control HIF activity, and represents a mechanism 
to independently control HIFα levels in hypoxic cells [23]. 
4. Control of Protein Synthesis in Hypoxia 
Cellular control of mRNA translation may be global, in which the translation of the bulk of the 
mRNAs is regulated en masse, or mRNA specific, wherein the translation of defined subsets of 
mRNAs is modulated [24,25]. In cells and tissues exposed to hypoxia, disruptions to oxygen delivery 
results in decreased energy production and general suppression of energy expensive processes such 
as protein synthesis [2,9]. Under severe hypoxia, the ATP demand for protein synthesis drops to 
approximately 7% of normoxic cells, correlating with a dramatic reduction in protein translation rates 
[26]. Hypoxia-dependent repression of protein synthesis occurs mostly at the levels of translation 
initiation, generally considered to be the rate limiting step of protein translation [25]. Initiation occurs 
as the small ribosome subunit is recruited to the 5′ end of mRNA and scans towards the start codon 
[25]. Hypoxia prevents eukaryotic translation initiation via two distinct pathways propagated by the 
mammalian target of rapamycin (mTOR) [27–29] and the stress responsive protein kinase R (PKR)-
like endoplasmic reticulum kinase (PERK) [30–32]. 
mTOR inhibition during hypoxia requires the action of the TSC1/TSC2 tumour suppressor 
complex and the hypoxia-inducible gene REDD1 [27,33]. Hypoxia triggers the release of the mTOR 
inhibitor TCS2 from 14-3-3 binding proteins in a REDD1-dependent manner to block mTOR activity, 
resulting in the hypophosphorylation of its effectors 4E-BP1, p70S6K and RPS6, ultimately leading to 
the inhibition of translation initiation [34–36]. This inhibition terminates the recruitment of the 
eukaryotic translation initiation factor 4F (eIF4F) complex to the 5′ cap structure of the mRNA 
transcript, culminating in translation block [34]. Interestingly, fibroblasts isolated from either TSC2 
or REDD1-null mice exhibit increased proliferation rates and anchorage-independent growth under 
hypoxia as a result of aberrant mTOR activity, suggesting that loss of mTOR-dependent control of 
protein synthesis in hypoxia is tumour promoting [27,33]. 
In addition, severe hypoxia can lead to the phosphorylation and activation of PERK, one of a 
family of kinases that can phosphorylate and inhibit eukaryotic translation initiation factor 2 alpha 
(eIF2 α) [36]. Phosphorylated eIF2 α acts as a dominant inhibitor of eIF2B, which effectively prevents 
the recycling of eIF2 between successive rounds of protein synthesis, thus causing a general 
suppression of translational initiation and global protein synthesis [36]. Severe hypoxia results in the 
PERK-dependent phosphorylation of eIF2 α in several different mouse and human cell lines [30,37]. 
Genetic evidence from PERK-null mice demonstrate its protective role during hypoxic stress. MEFs 
isolated from PERK-null mice were more sensitive to hypoxic stress than matched wildtype cells, 
indicating the importance of PERK-dependent signalling during the hypoxic response [30,31,37]. 
The evidence suggests that the HIF-, mTOR- and PERK-dependent responses to hypoxia act in 
an integrated way, impacting each other and the hypoxia-dependent signalling pathways that affect 
gene expression, metabolism, cell survival, tumorigenesis and tumour growth [29,38]. 
5. Specific Control of HIF Protein Translation in Hypoxia 
Repression of global protein synthesis, while necessary for the adaptive response to the changing 
energy conditions in hypoxia, is insufficient to trigger the adaptive response to restore oxygen 
homeostasis [39–42]. Overcoming translational repression during hypoxia is needed for de novo 
synthesis of proteins essential for the adaptive response to low oxygen. Translation of the HIF family 
of transcription factors and other proteins necessary for the hypoxic response is maintained to ensure 
cells have the correct repertoire of stress-responsive factors [23]. The specific control of mRNA-
specific translation is dependent on signals encoded within cis-elements present in the mRNA’s 5′- or 
3′-untranslated regions (UTRs). 
The preferential translation of HIFα subunits during hypoxia was originally attributed to an 
internal ribosome entry site (IRES) encoded within the 5′ UTR of mRNAs [43,44]. IRES sequences 
allow specific mRNAs to be translated independently of the global rates of protein synthesis as it 
serves as a ribosome assembly site in the middle of the mRNA, which is independent from the eIF4F 
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cap-binding complex [45]. However, subsequent studies have indicated that the HIF UTRs do not 
possess IRES activity [46,47], instead regulatory non-coding RNAs and/or RNA-binding proteins 
together regulate translation rates via interaction with the 5′ and 3′ UTRs of HIF subunit mRNAs [48–
51]. 
MicroRNAs 
MicroRNAs (MiRs) are small noncoding RNAs that extensively regulate gene expression in 
animals, plants and protozoa [52,53]. Cellular stresses such as hypoxia induce the expression of a MiR 
signature that contributes to the changes in the proteome to restore oxygen homeostasis (Reviewed 
in [54–56]). Interestingly, the pattern of MiR activation under low oxygen is dependent on the type 
of hypoxic stress, with chronic hypoxia having a different signature to cyclic or intermittent hypoxia, 
adding an additional level of complexity to the system [57]. MiRs can directly post-transcriptionally 
regulate HIF transcription factors by binding to the mRNA 3’-untranslated regions reducing their 
half-life and/or inhibiting their translation [56,58,59]. Several MiRs have been described that bind 
directly to the 3′ UTR of the HIF1α transcript to suppress HIF1α levels, including MiR-155 [60], MiR-
429 [61] [62], MiR-519c [63], MiR-17-92 cluster [64–66], MiR-153 [67], MiR-199a [68], MiR-150 [69] and 
MiR-497 [70] (detailed in Table 1). MiR-155, MiR-429 and MiR-153 are induced in low oxygen as part 
of the hypoxia-induced MiR signature, perhaps representing an isoform-specific negative feedback 
loop for the resolution of HIF1α activity in cells exposed to prolonged hypoxia [60–62,67]. Although 
the other identified MiRs do not seem to be induced by hypoxia, they can directly alter HIF1α 
expression and reduce HIF-dependent angiogenesis and tumour survival in multiple cancer cell 
types including lung, breast and gastric carcinoma cell lines [63–71], representing an isoform-specific 
control of HIF isoforms in malignant cells. 
Table 1.  MicroRNAs (MiRs) that directly degrade Hypoxia-Inducible Factor (HIF) subunit mRNA. 
Target mRNA MiR Response to Hypoxia MiR Binding Site(s) Reference 
HIF1α MiR-17-5p Repressed 3520/ 3738 57, 58, 59 
HIF1α MiR-18a Repressed 3042 57, 58, 59 
HIF1α MiR-20a Repressed 3027/ 3190 57, 58, 59 
HIF1α MiR-20b Repressed 3737 57, 58, 59 
HIF1α MiR-153 Induced 3446 60 
HIF1α MiR-155 Induced 3799 53 
HIF1α MiR-199a-5p Not Tested 2810 61 
HIF1α MiR-210 Induced 2884 50, 63 
HIF1α MiR-429 Induced 3218 54, 55 
HIF2α MiR-30a-3p Not Tested 4993 67 
HIF2α MiR-30c-2-3p Not Tested 4006 67 
HIF2α MiR-145 Not tested 3919 66 
HIF3α MiR-429 Induced 4301 55 
HIF1β MiR-107 Induced 3361 50, 68 
Indicated in the table is the MiR, the specific HIF substrate targeted, the position within the mRNA 
that the MiR binds and if the MiR expression level itself is regulated by low oxygen. All presented 
numbers are based on the nucleotide sequence of NM_001530 (HIF1A), NM_001430.5 (HIF2A), 
NM_152794.3 (HIF3A) and NM_001668.4 (HIF1B) and represent the nucleotide position in the mRNA 
that binds to the 5’ nucleotide of the MiR. 
A distinct subset of MiRs targeting HIF1β, HIF2α and HIF3α have been identified, mainly in 
tumour cell lines. However, their regulation appears to be hypoxia-independent [62,72–74] (Table 1). 
MiR-145, MiR-30a and MiR-30c can directly target the HIF2α 3′ UTR, suppressing HIF2α without 
altering the levels or activity of HIF1α, again demonstrating that differential MiR expression may 
represent a mechanism to control isoform-specific regulation of HIF transcription factors [72,73]. The 
difference in the numbers of MiRs identified targeting HIF1α mRNA, rather than HIF2α mRNA, 
more than likely represents the greater research focus on the activity of the HIF1α subunit, as the 
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HIF2α mRNA’s 3′ UTR is approximately double the length of the HIF1α mRNA 3′ UTR (2064bp 
compared to 1197bp), suggesting additional HIF2α -specific MiRs are yet to be identified. 
6. RNA-Binding Proteins and Their Role in HIF Subunit Translation 
In addition to the encoding information that mediates the RNA/RNA interactions essential for 
the MiR-dependent control of HIF activity, the 5′ and 3′ UTRs of HIF subunits also form structures 
that can mediate interactions with RNA-binding proteins (RBPs) that profoundly affect their 
translation rates in human cells (Figure 1). Outlined below is a selection of the RNA binding proteins 
that can influence HIF subunit translation rates. 
 
Figure 1. Schematic of the HIFα mRNAs and their RNA-binding proteins (RBPs). Schematic showing 
the known HIF1α and HIF2α RBPs, the region of the mRNA they are known to bind to and the known 
physiological modulators of HIF1α and HIF2α translation rates. The positions of the start of the 5’ 
UTR, coding region and the 3’ UTR are taken from the nucleotide sequences NM_001530 (HIF1A) and 
NM_001430.5 (HIF2A). 
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6.1. Y Box Binding Protein 1 
Y box binding protein 1 (YB-1) is a highly conserved cold shock domain (CSD) family protein 
that can bind to both DNA and RNA [75,76]. YB-1 participates in a wide variety of DNA/RNA-
dependent events including DNA repair, transcription, mRNA splicing and packaging, and 
regulation of mRNA stability and protein translation [75,76],. Unbiased mapping of the RNA species 
that interact with YB-1 in vivo reveal that the vast majority of YB-1/mRNA interactions occur either 
in the protein encoding regions or the 3′ UTRs of mRNAs and are thought to facilitate storage and 
repression of mRNA translation [77]. YB-1 can also induce the expression of certain stress-responsive 
factors by binding to the 5′ UTR of mRNAs to increase their translation rates [78,79]. One such mRNA 
that is positively regulated by YB-1 binding to its mRNA is HIF1α. YB-1 directly binds to a region 
within 5′ UTR of HIF1α to promote its translation [80]. The YB-1-HIF1α mRNA interaction is 
enhanced in hypoxic cells, creating a feed forward mechanism to maintain HIF1α translation in 
response to low oxygen [81]. HIF1α mRNA translation rates are dependent on the YB-1 interaction 
in hypoxic cells. Our lab has found that the YB-1/HIF1α mRNA interaction is negatively regulated by 
the activation of protein kinase, PERK, in moderate hypoxia, suggesting that activation of the UPR 
can have different effects depending on the severity of hypoxic stress [81]. Like the HIF proteins 
themselves, YB-1 expression has been correlated with the progression or severity of neoplastic 
diseases including lung, breast, gastric and colon cancers (reviewed in [82]). As high HIF levels and 
activity are characteristic of many of these tumour types, the oncogenic activity of YB-1 may be due 
to its role in regulating the HIF pathway. 
6.2. Hu Antigen R 
Hu Antigen R (HuR) is a ubiquitously expressed RNA-binding protein involved in the 
regulation of translation by directly binding to the conserved RNA sequence motifs of a variety of 
stress-responsive proteins [83]. HuR binds to a large number of mRNAs bearing AU- and U-rich UTR 
sequences and transcriptome wide analysis reveals ~26,000 endogenous HuR binding sites, binding 
up to 4874 mRNA sequences, representing about half the transcripts in a HeLa cell [51,83]. HuR 
knockdown leads to a highly significant destabilisation of transcripts with HuR binding sites, 
confirming its role in regulating mRNA stability [51]. HIF1α mRNA, but not any other HIF subunit, 
has been identified as a HuR target in both candidate-based [84,85] and unbiased screens [51]. HuR 
can bind to both the 5′ and 3′ UTRs of the HIF1α mRNA in human cells [84] [85]. HuR binding to the 
5′ UTR of HIF1α is surprising as this region of HIF1α mRNA is extremely GC-rich. However, 
experimental evidence suggests the overexpression of HuR dramatically increases the translation of 
a reporter transcript fused to the HIF1α 5′ UTR sequence. Interestingly, no observable difference is 
seen in translation rates using a 3′ UTR-containing reporter construct [85]. The link between HuR 
promoting HIF1α mRNA translation is supported in subsequent studies examining the pro-
oncogenic properties of HuR in meningioma, in which HuR depletion suppresses the HIF1 signalling 
pathway [86]. 
6.3. Polypyrimidine Tract Binding Protein 
Like YB-1 and HuR, the polypyrimidine tract binding protein (PTB) can regulate multiple steps 
in the mRNA lifecycle from splicing, localisation and storage to translation [87,88]. PTB is 
ubiquitously expressed in mammalian cells and binds with high affinity for tracts of polypyrimidine 
(CU) – motifs in RNA [87,89]. PTB has been characterised as an enhancer of HIF1α translation through 
binding to the HIF1α UTR in cultured human kidney cells in a manner similar to YB-1 [43]. Further 
studies found that instead of exclusively binding to the 5′ UTR of HIF1α, PTB could bind to both the 
5′ and 3′ UTR to promote HIF1α translation [85]. PTB homodimers contain four RNA-binding 
domains (RBDs); the role of PTB may only be clear in the context of the whole mRNA sequence rather 
than in reporter assays. Structural studies have shown that the RBDs of PTB each bind with a subtly 
different binding specificity, allowing a single PTB molecule to create RNA loops in a target mRNA, 
facilitating splicing, or modulating the mRNA structure [89]. Due to the presence of PTB binding sites 
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in both the 5′ and 3′ UTR of the HIF1α mRNA, it is possible that PTB, along with other HIF1α mRNA 
RBPs, can create mRNA loops to facilitate ribosome recycling [90]. Although many of these studies 
have examined the effects of RNA binding proteins in isolation, the available evidence suggests that 
a single HIF1α mRNA can bind to multiple RBPs. Indeed, there appears to be co-operation between 
PTB and HuR in promoting HIF1α translation in reporter assays [85]. 
6.4. Tristetraprolin 
Additional control of the HIF1α 3′ UTR is provided by the Tristetraprolin (TTP) family of RNA 
binding proteins [91] [92]. The human TTP family consists of three members, TTP (TIS11/ZFP36), 
TIS11b (ZFP36L1/BRF1) and TIS11d (ZFP36L2/BRF2), which own the same characteristic CCCH 
tandem zinc-fingers and share similar mRNA-destabilising activity in vitro [93,94]. The 
overexpression of each of the three family members can suppress the expression of a HIF1α 3′ UTR 
reporter construct through the control of mRNA stability [92]. TTP family members bind to AU-rich 
elements within the UTRs of a variety of genes and endogenous TTP physically interacts with HIF1α 
mRNA as measured by RNA IP [92]. In the case of the HIF1α transcript, TTP can bind to a well-
defined region in the 3′ UTR of HIF1α and induce its degradation [91] [92]. siRNA knock down 
experiments show that TTP can specifically destabilise HIF1α mRNA in cells exposed to prolonged 
hypoxia, but not normoxic cells, perhaps indicating that TTP plays a role in a hypoxia-specific HIF1 
negative feedback loop [91,92]. The mRNAs targeted by TTP encode protein products such as HIF1α, 
which are critical for the progression of several malignancies [95–98]. The loss of TTP has been 
reported in several human cancers; this correlates with the elevation of HIF1α and poor prognosis 
[95–98]. 
6.5. RNA Binding Motif Protein 38 
RNA Binding Motif Protein 38 (RBM38) is an additional RNA-binding protein that associates 
with the AU-rich elements in the 3′ UTR of the HIF1α mRNA [99]. Like PTB, RBM38 can also bind to 
the GC-rich 5′ UTR of HIF1α mRNA as demonstrated by EMSA and RNA IP [99]. RNA IP and EMSA 
show that the binding of RBM38 to the 5′ UTR and 3′ UTR of HIF1α mRNA prevents the association 
of eIF4E with the 5′ cap of the HIF1α mRNA [99]. Moreover, RBM38 provides a link between the p53 
tumour suppressor and the hypoxia signalling pathway. RBM38 expression is under direct control of 
p53. Therefore, the loss of p53 diminishes the inhibitory effect of RBM38 on HIF1 activity to promote 
the malignant phenotype [99,100]. This is another example of how the loss of p53 can promote 
tumorigenesis by activating the HIF pathway to promote angiogenesis and changing energy 
metabolism. 
6.6. Cytoplasmic Polyadenylation Element Binding Proteins 1 and 2 
Cytoplasmic Polyadenylation Element Binding (CPEB) proteins bind to cytoplasmic 
polyadenylation elements (CPEs) in the 3′ UTRs of specific mRNAs to regulate poly (A) tail growth 
or removal, which promotes or represses translation. CPEB1, and to a lesser extent CPEB2, bind the 
CPE-containing fragment at the very 3′ end of the HIF1α mRNA [101]. Overexpressing CPEB1 and 2 
decreases HIF1α protein levels and alters the expression of HIF-target gene expression in cultured 
cells, indicating that the CPEB1 can alter HIF1α translation rates in cells [101]. Reduced levels of 
CPEB1 are associated with several types of cancer, cell invasion and angiogenesis, processes which 
correlate with high HIF activity [102,103]. 
6.7. Cold-Inducible RNA Binding Protein 
A recent study has described a role for the cold-inducible RNA-binding protein (CIRBP) as a 
novel modulator of HIF1α translation in human bladder cancers. CIRBP has been reported to be pro-
tumorigenic in a number of human cancers [104]. CIRBP binds specifically to the 3′ UTR of the HIF1α 
transcript to increase its stability and elevate HIF1α protein synthesis [104]. The depletion of CIRBP 
using RNAi suppressed HIF1α levels to reduce the proliferation and migration of bladder cancer cell 
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lines. This again provides further evidence of how inappropriate expression-specific RBPs can alter 
HIF activity in disease. 
6.8. Iron Regulatory Proteins 
Iron is an essential element in all living organisms and is required as a cofactor for oxygen-
binding proteins. Iron metabolism, oxygen homeostasis and erythropoiesis are consequently strongly 
interconnected, with iron acting as an essential cofactor of many oxygen-binding proteins [105]. Iron 
regulatory proteins (IRPs) control iron metabolism by binding to specific non-coding sequences 
within an mRNA, known as iron-responsive elements (IRE). IREs are 30 nucleotide long RNA motifs 
that form special stem-loop structures that reside in the 3′ UTR and 5′ UTRs of an mRNA. Analysis 
of the HIF2α mRNA revealed a conserved, functional iron-responsive element (IRE) in its 5′ UTR 
[106]. Low concentrations of iron increase the binding of IRP1 to the 5′ UTR of the HIF2a mRNA, 
repressing HIF2α translation rates and protein levels [106,107]. The disruption of mouse IRP1 leads 
to profound HIF2α-dependent abnormalities in erythropoiesis and systemic iron metabolism [108]. 
7. Direct Regulation of Protein Translation by HIF2α 
Many studies have demonstrated that translational control of the HIF subunits controls the 
length and intensity of the HIF-dependent hypoxic response. However, a recent study has suggested 
that HIF2α itself can act as a direct regulator of the translational rates of a subset of hypoxia-induced 
target genes [33]. Acting as part of a tripartite structure composed of the RNA binding protein, RBM4, 
and the translational regulator, eIF4E2, HIF2α captures the 5′cap and targets specific mRNAs, such 
as the EGFR mRNA to polysomes [33]. This represents a previously unanticipated role of HIF 
transcription factors playing a direct role in shaping the cellular proteome in response to hypoxic 
stress. 
8. Control of Messenger RNA Subcellular Localisation 
The localisation of mRNA is coupled to translational regulation and can provide an important 
means of controlling the expression of the cellular proteome. The localisation of mRNAs to discrete 
subcellular locations in the cytoplasm can have profound effects on the translation rates of specific 
mRNAs [109,110]. Control of mRNA subcellular localisation, once considered a specialised 
mechanism restricted to a very small fraction of transcripts controlling cell polarity or migration, is 
emerging as a conserved process regulating mRNA translation in a variety of cellular events. Studies 
performed in hypoxic yeast cells indicate a rapid subcellular redistribution of RNA-associated 
proteins involving mRNA splicing, cleavage and processing [111]. The unbiased measurement of 
mRNA localisation in hypoxic human fibrosarcoma cells reveals a shift in HIF1α transcripts to the 
ER-associated ribosomes upon the induction of hypoxic stress compared to normoxic controls [112]. 
The ER is a privileged site of protein synthesis in stressed cells, as such global rearrangement of the 
mRNAs represents a mechanism to switch the translational profile of stressed cells. Increased levels 
of ER-associated transcripts were observed in hypoxic cells [112], indicating the presence of 
conserved stress-responsive sequences within the UTRs of mRNAs that allow the co-ordinated 
expression of the hypoxia responsive proteome in low oxygen [112]. The mechanisms that direct 
mRNA partitioning by cis-element/ trans-factor interaction during hypoxia are unclear. However, as 
YB-1, HuR and PTB can rapidly relocalise in conditions of cell stress [78,113],, it is tempting to 
speculate that the relocalisation is, in part, due to the UTR RBPs discussed earlier in this review. 
9. HIF Translation—A Potential Therapeutic Target? 
As hypoxia and key hypoxia effectors such as HIF contribute to the pathologies of several human 
diseases, there is a great deal of interest in developing novel therapeutics to modulate HIF activity 
[1]. Small molecule inhibitors of the PHD and VHL enzymes that can hyperactivate HIF signalling 
have been developed to offer potential therapeutics for conditions where lack of HIF activity is 
pathogenic [2,114,115]. Currently, several PHD inhibitors are in clinical trials to enhance HIF activity 
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in anaemic patients to boost red blood cell production [116]. The development of small molecules 
that inhibit aberrant HIF activity, particularly in the context of cancer therapeutics, is complicated by 
the conflicting roles of HIF1 and HIF2 in certain tumour types [117]. Optimal HIF inhibitors would 
ideally allow differentiation between the HIF1α and HIF2α subunits. However, existing molecule 
inhibitors targeting HIF dimerisation, nucleic acid binding and transcriptional activity alter the 
activity of both HIF1 and HIF2 [118]. 
As discussed in this review, HIF1α and HIF2α are regulated by a distinct set of translational 
activators, offering an opportunity to differentiate between HIF1 and HIF2 therapeutically. Indeed, a 
number of structurally and functionally distinct drugs capable of modulating HIF translation have 
been identified that appear to have preference for specific subunit complexes. In our lab, we have 
described how the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) inhibitor thapsigargin 
disrupts the association of the RBP, YB-1, with HIF1α mRNA specifically repressing HIF1α levels and 
activity without altering HIF2α [81]. Conversely, arsenite enhances HIF1 activity by inhibiting the 
binding of CEPB2 to the 3′ UTR of HIF1α mRNA, enhancing the production of the protein [119]. In 
addition to its role in inhibiting the PHD enzymes, CoCl2 also enhances HIF1α protein production 
through stimulating the association of HuR and PTB to the UTRs [85]. 
An unbiased screen using a HIF reporter cell line identified an array of cardiac glycosides that 
can inhibit HIF1α translation independently of oxygen level in a UTR-dependent manner [120]. In 
addition, the DNA alkylating agent mitomycin C, the topoisomerase inhibitor camptothecin, and the 
anti-clotting agent YC-1 also decrease HIF1a protein levels through the 5′ UTR of its mRNA without 
affecting mRNA stability [121]. 
The HIF2α mRNA/IRP1 interaction can also be exploited pharmacologically to specifically 
modulate HIF2 activity, without altering the levels and activity of HIF1α. An unbiased screen to 
identify novel HIF therapeutics identified selective inhibitors of HIF2α translation [106]. Hypoxia 
derepresses HIF2α translation by disrupting the IRP1/HIF2α mRNA interaction [122]. The small 
molecule identified in this study promotes and restores the IRP/HIF2α mRNA interaction to 
specifically repress HIF2 without altering HIF1 activity [107,122]. 
10. Perspective 
Since its discovery over 25 years ago, great advances have been made in our understanding of 
the role of the HIF family of transcription factors in normal physiological responses and disease. The 
series of post-translational modifications that control the oxygen-dependent degradation of the HIFα 
subunits is well-defined and understood. However, it is becoming clear that targeted control of 
protein synthesis is critical for controlling HIF levels and activity in response to low oxygen. As we 
gain deeper knowledge of the how the RBPs and non-coding RNAs control HIF mRNAs, their 
potential usefulness as therapeutic targets is becoming apparent. As the factors controlling HIF1α 
and HIF2α mRNA are distinct, this offers the opportunity to target these complexes separately. 
Advances have been made in identifying several modulators of HIF translation rates. However, much 
of this work has relied on reporter assays rather than the direct measurement of translation rates. 
Careful, systematic, analysis of the role of RNA binding proteins and MiRs that direct HIF subunit 
translation is needed if these pathways are to be clinically exploited. 
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